mhb088c
mAbexperimentalADC
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jan 23, 2023 (NCT05652855)
Timeline
Indications
Mechanism of action
- CD276 antigenBINDING AGENT
B7H3
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07126665 | Phase 1/Phase 2 (Phase 2) | Sep 18, 2025 | Minghui Pharmaceutical Pty Ltd |
| NCT06954246 | Phase 3 | Jun 4, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT06951243 | Phase 2 | May 6, 2025 | Government of China |
| NCT07102004 | Phase 1/Phase 2 (Phase 2) | Jun 20, 2023 | Qilu Pharmaceutical Co., Ltd. |
| NCT05652855 | Phase 1/Phase 2 (Phase 2) | Jan 23, 2023 | Minghui Pharmaceutical Pty Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Minghui Pharmaceutical Pty Ltd | For profit | 2 | 2 | 1 | 2023 |
| Qilu Pharmaceutical Co., Ltd. | For profit | 2 | 2 | 2 | 2023 |
| Government of China | Government | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1